BioSpace News Archive

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in PHALCON-HP, a pivotal Phase 3 clinical trial of vonoprazan in combination with amoxicillin (vonoprazan dual therapy) and vonoprazan in combination with amoxicillin and clarithromycin

Ortho Clinical Diagnostics Holdings plc (“Ortho”), the world’s largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the launch of its initial public offering of its ordinary shares

The VHL Alliance announced the 2021 recipients of the VHLA Competitive Research Grant Program.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the publication of a recent review article in Medicine in Drug Discovery featuring data on its novel NMDA receptor modulator, NYX-2925.

Sparta Group’s TruckSuite™ division has made transport truck breakdowns a lot less stressful, as well as less costly thanks to the introduction of a special stress-free Repair Financing program.

Expands Blue Spark’s research capabilities into predictive machine learning and AI algorithms for predictive disease states

Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced the publication of its global WIPO/PCT Patent WO 2020/ 264324 – “Use of Certain Phosphatidylcholines Containing Long Chain Polyunsaturated Fatty Acids (“PUFAs”) as Neuroprotective Agents” (the “PUFA Patent”).

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock.

Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced positive results from a study using MI GPSai™ an artificial intelligence driven product using DNA sequencing and whole transcriptome data to aid in the diagnosis of cancer.

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus’ proprietary Biclonics® platform